Guselkumab Adds PsA Structural Damage Inhibition to Label
The FDA has approved guselkumab for the inhibition of structural joint damage in adults with active psoriatic arthritis. This makes guselkumab the only IL-23 inhibitor confirmed to prevent further structural damage in these patients. The approval is based on a study showing significant benefits compared to placebo.
- ▪Guselkumab is now approved to inhibit structural damage in adults with active psoriatic arthritis.
- ▪It is the only IL-23 inhibitor proven to help stop further structural damage in patients with active PsA.
- ▪The approval is based on a phase 3b study showing a 2.5 times greater inhibition of structural damage compared to placebo.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/guselkumab-adds-psoriatic-arthritis-structural-damage-2026a1000i12?src=rss |
| Publication time | Fri, 29 May 2026 13:39:20 EDT |
| Retrieval time | 2026-05-29T17:50:02.698Z |
| Last seen | 2026-05-29T17:50:02.698Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | NAF1ufJuBdv8 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The FDA has approved a supplemental biologics license application for the interleukin (IL)-23 inhibitor guselkumab to include evidence for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA), according to a May 28 announcement from Johnson & Johnson, the parent company of guselkumab’s manufacturer, Janssen Biotech.The approval confirms that guselkumab is the only IL-23 inhibitor that has been proven to help stop further structural damage in patients with active PsA, setting it apart from risankizumab — another IL-23 inhibitor approved to treat PsA — and the IL-12/IL-23 inhibitor ustekinumab, which is also approved to treat PsA.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
